← Leaderboards
Joann Elisabeth Manson
Brigham And Women'S Hospital
$50,755,529
Attributed
$86,258,341
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$86,258,341 · 10
By mechanism
R01$44,384,606 · 5
U01$41,405,536 · 2
N01$400,769 · 1
M01$67,430 · 2
Top collaborators
- Julie E Buring21 shared
- Jorge Eduardo Chavarro12 shared
- Lu Qi10 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Julie E Buring$63,823,301
- Susan Cheng$21,020,819
- Meryl S Leboff$9,246,227
- Mohit Jain$6,712,308
- Olivia Ifeoma Okereke$11,031,577
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanParticipantRisk FactorsCardiovascular DiseasesFollow-UpEventMedical RecordsCardiovascular Risk FactorCohortStrokeQuestionnairesResourcesBlood SpecimenBiological MarkersReportingMyocardial InfarctionFutureDesignDietDiabetes MellitusBaseBiochemicalCoronary Heart DiseasePersons
Grant awards (75)
Integrating lifecourse approaches, biologic and digital phenotypes in support of heart and lung disease epidemiologic research$2,406,134
U01 · FY2025 · HL
The VITamin D and OmegA-3 TriaL (VITAL): Post-Intervention Follow-Up$765,000
R01 · FY2025 · AT · contact PI
RISK FACTORS FOR CVD IN WOMEN$738,875
R01 · FY2025 · HL
Integrating lifecourse approaches, biologic and digital phenotypes in support of heart and lung disease epidemiologic research$126,107
U01 · FY2025 · HL
Integrating lifecourse approaches, biologic and digital phenotypes in support of heart and lung disease epidemiologic research$2,386,879
U01 · FY2024 · HL
The VITamin D and OmegA-3 TriaL (VITAL): Post-Intervention Follow-Up$833,001
R01 · FY2024 · AT · contact PI
RISK FACTORS FOR CVD IN WOMEN$767,670
R01 · FY2024 · HL
Integrating lifecourse approaches, biologic and digital phenotypes in support of heart and lung disease epidemiologic research$129,058
U01 · FY2024 · HL
Integrating lifecourse approaches, biologic and digital phenotypes in support of heart and lung disease epidemiologic research$2,477,414
U01 · FY2023 · HL
The VITamin D and OmegA-3 TriaL (VITAL): Post-Intervention Follow-Up$850,000
R01 · FY2023 · AT · contact PI
The VITamin D and OmegA-3 TriaL (VITAL): Post-Intervention Follow-Up$266,293
R01 · FY2023 · AT · contact PI
Integrating lifecourse approaches, biologic and digital phenotypes in support of heart and lung disease epidemiologic research$130,972
U01 · FY2023 · HL
Integrating lifecourse approaches, biologic and digital phenotypes in support of heart and lung disease epidemiologic research$2,501,827
U01 · FY2022 · HL
The VITamin D and OmegA-3 TriaL (VITAL): Post-Intervention Follow-Up$850,000
R01 · FY2022 · AT · contact PI
Risk Factors for CVD in Women$780,454
R01 · FY2022 · HL · contact PI
Childhood and Adult Psychosocial Stress and the Association with Disparities in Adult Cardiometabolic Health$98,113
U01 · FY2022 · HL
Integrating lifecourse approaches, biologic and digital phenotypes in support of heart and lung disease epidemiologic research$2,529,652
U01 · FY2021 · HL
The VITamin D and OmegA-3 TriaL (VITAL): Post-Intervention Follow-Up$850,000
R01 · FY2021 · AT · contact PI
Risk Factors for CVD in Women$781,748
R01 · FY2021 · HL · contact PI
Changes in Dietary Supplement Use During the COVID-19 Pandemic$205,108
U01 · FY2021 · HL
Integrating lifecourse approaches, biologic and digital phenotypes in support of heart and lung disease epidemiologic research$2,502,282
U01 · FY2020 · HL
Risk Factors for CVD in Women$781,114
R01 · FY2020 · HL · contact PI
The VITamin D and OmegA-3 TriaL (VITAL)$3,368,726
R01 · FY2019 · CA · contact PI
Integrating lifecourse approaches, biologic and digital phenotypes in support of heart and lung disease epidemiologic research$2,338,008
U01 · FY2019 · HL
Risk Factors for CVD in Women$845,852
R01 · FY2019 · HL · contact PI
The VITamin D and OmegA-3 TriaL (VITAL)$200,000
R01 · FY2019 · CA · contact PI
The VITamin D and OmegA-3 TriaL (VITAL)$3,474,603
R01 · FY2018 · CA · contact PI
The VITamin D and OmegA-3 TriaL (VITAL)$200,000
R01 · FY2018 · CA · contact PI
The VITamin D and OmegA-3 TriaL (VITAL)$4,413,440
R01 · FY2017 · CA · contact PI
Risk Factors for CVD in Women$557,489
R01 · FY2017 · HL · contact PI
The VITamin D and OmegA-3 TriaL (VITAL)$200,000
R01 · FY2017 · CA · contact PI
The VITamin D and OmegA-3 TriaL (VITAL)$4,377,141
R01 · FY2016 · CA · contact PI
Risk Factors for CVD in Women$561,034
R01 · FY2016 · HL · contact PI
The VITamin D and OmegA-3 TriaL (VITAL)$186,100
R01 · FY2016 · CA · contact PI
The VITamin D and OmegA-3 TriaL (VITAL)$4,335,161
R01 · FY2015 · CA · contact PI
Risk Factors for CVD in Women$551,976
R01 · FY2015 · HL · contact PI
The VITamin D and OmegA-3 TriaL (VITAL)$185,925
R01 · FY2015 · CA · contact PI
VITamin D and omegA-3 triaL (VITAL)$1,849,394
U01 · FY2014 · CA · contact PI
Risk Factors for CVD in Women$592,781
R01 · FY2014 · HL · contact PI
VITamin D and omegA-3 triaL (VITAL)$136,162
U01 · FY2014 · CA · contact PI
VITamin D and omegA-3 triaL (VITAL)$3,475,391
U01 · FY2013 · CA · contact PI
VITamin D and omegA-3 triaL (VITAL)$154,236
U01 · FY2013 · CA · contact PI
VITamin D and omegA-3 triaL (VITAL)$3,391,568
U01 · FY2012 · CA · contact PI
Risk Factors for CVD in Women$560,563
R01 · FY2012 · HL · contact PI
VITamin D and omegA-3 triaL (VITAL)$167,479
U01 · FY2012 · CA · contact PI
VITamin D and omegA-3 triaL (VITAL)$4,428,648
U01 · FY2011 · CA · contact PI
Risk Factors for CVD in Women$565,713
R01 · FY2011 · HL · contact PI
VITamin D and omegA-3 triaL (VITAL)$4,819,957
U01 · FY2010 · CA · contact PI
Risk Factors for CVD in Women$571,429
R01 · FY2010 · HL · contact PI
VITamin D and omegA-3 triaL (VITAL)$5,151,147
U01 · FY2009 · CA · contact PI
Risk Factors for CVD in Women$571,522
R01 · FY2009 · HL · contact PI
Risk Factors for CVD in Women$560,294
R01 · FY2008 · HL · contact PI
THE KRONOS EARLY ESTROGEN PREVENTION STUDY (KEEPS)$8,754
M01 · FY2008 · RR · contact PI
THE KRONOS EARLY ESTROGEN PREVENTION STUDY (KEEPS)$58,676
M01 · FY2007 · RR · contact PI
Risk Factors for CVD in Women$519,305
R01 · FY2006 · HL · contact PI
Trial of Antioxidant Therapy of CVD in Women$627,935
R01 · FY2005 · HL
Risk Factors for CVD in Women$516,935
R01 · FY2005 · HL
Trial of Antioxidant Therapy of CVD in Women$41,920
R01 · FY2005 · HL
BIOCHEMICAL AND GENETIC MARKERS OF TYPE 2 DIABETES RISK$620,998
R01 · FY2004 · DK
Trial of Antioxidant Therapy of CVD in Women$598,635
R01 · FY2004 · HL
Risk Factors for CVD in Women$475,132
R01 · FY2004 · HL
BIOCHEMICAL AND GENETIC MARKERS OF TYPE 2 DIABETES RISK$606,794
R01 · FY2003 · DK
Trial of Antioxidant Therapy of CVD in Women$591,750
R01 · FY2003 · HL
Risk Factors for CVD in Women$427,236
R01 · FY2003 · HL
BIOCHEMICAL AND GENETIC MARKERS OF TYPE 2 DIABETES RISK$601,260
R01 · FY2002 · DK
Trial of Antioxidant Therapy of CVD in Women$598,353
R01 · FY2002 · HL
Risk Factors for CVD in Women$394,009
R01 · FY2002 · HL
Risk Factors for CVD in Women$206,873
R01 · FY2002 · HL
BIOCHEMICAL AND GENETIC MARKERS OF TYPE 2 DIABETES RISK$573,972
R01 · FY2001 · DK
TRIAL OF ANTIOXIDANT THERAPY OF CVD IN WOMEN$571,758
R01 · FY2001 · HL
RISK FACTORS FOR CVD IN WOMEN$361,118
R01 · FY2001 · HL
TRIAL OF ANTIOXIDANT THERAPY OF CVD IN WOMEN$555,713
R01 · FY2000 · HL
VANGUARD CENTER FOR WOMEN'S HEALTH INITIATIVE$400,769
N01 · FY2000 · WH
RISK FACTORS FOR CVD IN WOMEN$351,006
R01 · FY2000 · HL
VANGUARD CENTER FOR WOMEN'S HEALTH INITIATIVE$0
N01 · FY2000 · WH